^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Xtandi (enzalutamide) (Androgen receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
Published date:
07/01/2020
Excerpt:
Of the three responders with baseline biopsies, one had MSI high disease with mutations consistent with DNA-repair defects. Pembrolizumab has activity in mCRPC when added to enzalutamide.
DOI:
10.1136/jitc-2020-000642
Trial ID:
